Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (41 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (Po0.0001). Risk-adapted, treosulfan-based therapy with auto-and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation. Keywords: relapsed non-Hogkin's lymphoma; treosulfan; autologous transplantation; allogeneic transplantation; risk-adapted therapy INTRODUCTION High-dose chemotherapy with auto-SCT has been the standard approach for relapsed aggressive non-Hodgkin's lymphoma (NHL) since the PARMA trial, 1 which reported a higher 5-year OS rate (53%) compared with that of conventional chemotherapy only (32%). Disease-free survival after a high-dose therapy is higher in cases of chemosensitive relapse than in cases of chemoresistant relapse, 2 and cytoreductive salvage therapy is more efficient after late relapse than after early relapse. 3 The application of allogeneic transplantation for these patients has evolved at a slower pace,
INTRODUCTION
High-dose chemotherapy with auto-SCT has been the standard approach for relapsed aggressive non-Hodgkin's lymphoma (NHL) since the PARMA trial, 1 which reported a higher 5-year OS rate (53%) compared with that of conventional chemotherapy only (32%). Disease-free survival after a high-dose therapy is higher in cases of chemosensitive relapse than in cases of chemoresistant relapse, 2 and cytoreductive salvage therapy is more efficient after late relapse than after early relapse. 3 The application of allogeneic transplantation for these patients has evolved at a slower pace, [4] [5] [6] [7] [8] and a treatment-related mortality greater than 40% has led to the questioning of its role. 9 Treosulfan is an alkylating agent with a steep dose-response curve. High-dose treosulfan and fludarabine before allogeneic transplantation has shown efficacy with little toxicity in AML and myelodysplastic syndromes. 10, 11 Treosulfan has also been investigated as a high-dose therapy before auto-SCT in ovarian cancer and other solid tumors. 12, 13 A previous study demonstrated its activity in a high-dose combination regimen for relapsed aggressive lymphoma, 14 thereby expanding the limited number of high-dose protocols.
The East German Study Group for Hematology and Oncology (OSHO) therefore undertook a prospective, risk-adapted, multicenter phase II trial (Trial 071) to evaluate treosulfan as part of a high-dose chemotherapy regimen for both auto-and allo-SCT in patients with relapsed or refractory aggressive NHL.
MATERIALS AND METHODS Patients
The study included patients with aggressive NHL (18-65 years old) either at first relapse or with refractory disease after first-line treatment. Exclusion criteria were central nervous system involvement by lymphoma, human immunodeficiency virus infection or organ transplantation. The term aggressive NHL includes high-grade malignancies, such as diffuse large B-cell lymphoma, follicular lymphoma grade 3, high-grade malignant lymphoma not otherwise specified and T-cell lymphoma with high proliferation rate.
Risk-adapted treatment stratification
All patients underwent cytoreduction with two cycles of dexamethasone, high-dose cytarabine, cisplatinum and rituximab (R-DHAP), followed by one course of high-dose (R)-TEC (details below) and autologous stem cell support. Patients with late relapse at study entry (duration of first CR 41 year) who achieved CR after (R)-DHAP received no further treatment (arm A); patients with late relapse who achieved CR or PR only after (R)-TEC received a second high-dose treatment with (R)-TEC (arm B); and patients with early relapse or refractory disease who achieved at least PR after (R)-TEC were scheduled for high-dose fludarabine and treosulfan followed by allo-SCT (arm C; Figure 1 ).
Therapy regimens
1. Initial cytoreduction with (R)-DHAP and autologous stem cell collection. For patients with B-cell NHL, rituximab (MabThera, Roche AG; 375 mg/m 2 , i.v. infusion) was administered on day 1, dexamethasone (40 mg/day i.v.) on days 1-4, cisplatinum (100 mg/m 2 , 24-h i.v. infusion) on day 1 and highdose cytarabine (2 Â 2 000 mg/m 2 i.v. at 12-hour intervals) on day 3. Filgrastim (5 mg/kg/day) was administered by s.c. injection for neutrophil recovery and blood stem cell mobilization after the second cycle of (R)-DHAP.
2. High-dose therapy with (R)-TEC, followed by auto-SCT. Patients with at least stable disease after two courses of (R)-DHAP proceeded to a highdose therapy. Rituximab was administered as detailed above on day À 5. On days À 4 to À 2, etoposide (500 mg/m 2 /day), treosulfan (Medac GmbH, Wedel, Germany; 14 g/m 2 /day) and carboplatinum (300 mg/m 2 /day) were given. SCT using at least 3 Â 10 6 CD34 þ cells/kg body weight was performed on day 0. Filgrastim (5 mg/kg/day) was given beginning day þ 5 until leukocyte counts reached 41000/mL. To reduce the severity and duration of oral mucositis, palifermin (Kepivance, Amgen; 60 mg/kg/day) was given from day À 8 to À 6 and from day 0 to þ 2.
The time interval for patients receiving a second high-dose therapy with auto-SCT (arm B) was 8-12 weeks after initiation of the first high-dose therapy. 10 allo-SCT from a matched related or unrelated donor was performed on day 0. GVHD prophylaxis consisted of cyclosporine (3 mg/kg/day i.v. from day À 1), MTX (15 mg/m 2 i.v. on day þ 1), and MTX (10 mg/m 2 /day on days þ 3 and þ 6). Patients with unrelated donors also received anti-thymocyte globulin (ATG-Fresenius; 10 mg/kg body weight/day) from days À 4 to À 2. Dosing of cyclosporine was adapted according to plasma or whole blood levels.
Study end points and statistical aspects
The primary study end points were feasibility and toxicity. Patients who underwent at least one cycle of therapy were assessable for per-protocol analysis. Toxicity was evaluated according to Common Toxicity Criteria version 3.0. Acute GVHD was evaluated in patients who survived at least 30 days, and chronic GVHD was assessed in patients with a follow-up of at least 100 days post transplant according to standard criteria.
For a reliable estimation of toxicity, a recruitment goal of approximately 60 patients was prospectively defined in order to have 30 patients complete the whole treatment strategy including autologous transplantation.
Secondary study end points included response to therapy by standard World Health Organization remission criteria. The imaging modality of choice was computed tomography scan. Follow-up analysis after end of treatment was performed every 3 months. Event-related end points were estimated by using the Kaplan-Meier method and compared between prognostic groups by the log-rank test. To compare toxicity rates, an exact version of the Mantel-Haenszel procedure was used. All P-values are two-sided.
Approval and registration of the study protocol
The study protocol was approved by the ethics committee of the University of Magdeburg and the ethics committees of each participating center. This study was conducted in accordance with the Declaration of Helsinki, the Standards of Good Clinical Practice (ICH-GCP), and the German law. The study was registered by ClinicalTrials.gov as NCT 00 384 553.
RESULTS

Patient characteristics
Between August 2004 and July 2009, 61 patients were enrolled. Four patients were excluded from analysis because of revision of lymphoma diagnosis (n ¼ 2) or protocol violation (n ¼ 2), leaving 57 patients for per-protocol analysis. Patient characteristics at study entry are shown in Table 1 . All 49 patients with B-cell lymphoma (86%) received a rituximab-containing, CHOP-based chemotherapy regimen during first-line therapy.
Completion of study protocol and early treatment termination Among the 57 evaluable patients, study treatment was discontinued after the first or second cycle of (R)-DHAP in 11 and 13 patients, respectively. In 18 of these patients (31.5%), treatment discontinuation was due to early disease progression. Other reasons for discontinuation after DHAP were patient's decision (two patients), septic shock or renal insufficiency (one patient each), and stem cell mobilization failure (two patients).
Of the 33 patients who underwent high-dose (R)-TEC with autologous transplantation, five patients received two courses (arm B), and 15 patients underwent high-dose chemotherapy followed by allo-SCT (arm C) (CONSORT diagram, Supplementary Information).
Stem cell mobilization and collection for autologous transplantation Stem cell mobilization and collection was successful in 33 of 35 patients. The mean stem cell yield was 8.0 ± 4.7 Â 10 6 CD34-positive cells/kg body weight.
Allogeneic transplantation Donor search was initiated at study entry for all patients with early relapse or refractory disease. Of 39 patients who qualified for allogeneic transplantation, only 15 (38%) actually received the assigned treatment due to early progression or toxicity. No lack of donors was reported. All allogeneic grafts were derived from peripheral blood. There were three matched related donors, 10 matched unrelated donors and two transplants with 9/10 matches (one HLA-A allele and one C-Ag-mismatch). A mean of 6.8 Â 10 Overall survival Figure 1 . OS of the entire study population.
High-dose therapy for relapsed aggressive lymphoma M Koenigsmann et al Toxicity 1. Non-hematologic toxicity after (R)-TEC. After high-dose (R)-TEC, the most frequent grade 3 or 4 adverse events in the 32 evaluated patients were oral mucositis (62%), infections (38%) and diarrhea (38%) ( Table 2 ). Grade 4 oral mucositis was observed in four patients (19%) who did not receive palifermin (P ¼ 0.38, MantelHaenszel test) but in none of the nine patients who received prophylactic treatment with palifermin. Of the five patients who received a second course of (R)-TEC, grade 3 non-hematologic toxicities occurred in two patients. These included vomiting, diarrhea and infection in one patient, and renal insufficiency, hypokalemia and infection in the other patient.
2. Hematologic toxicity and engraftment after high-dose (R)-TEC. Grade 4 leukopenia occurred in 91% of patients and thrombocytopenia in 81% after high-dose (R)-TEC. Engraftment of leukocytes 41000/mL occurred after the first and second cycles of (R)-TEC at a median of 11 days (range 8-15) and 10 days (range 9-25), respectively. Engraftment of platelets 420 000/mL was detected after the first and second cycles of (R)-TEC at a median of 13 days (range 0-41) and 10 days (range 8-11), respectively.
3. Engraftment after allogeneic transplantation. Engraftment of granulocytes 4500/mL and leukocytes 41000/mL was reached at a median of 19 days after allogeneic transplantation, engraftment of platelets was reached after a median of 22 days (420 000) and 25 days (450 000/mL). One patient reached a platelet count 450 000/mL after a prolonged time period of 129 days.
GVHD.
Acute GVHD was evaluable in 11 patients (grade 0, n ¼ 5 (45%)); (grade 1, n ¼ 1 (9%)); (grade 2, n ¼ 1 (9%)); and (grade 3, n ¼ 4 (36%))); (grade 4, n ¼ 0 (0%))). Of the seven patients evaluable for chronic GVHD, four patients (57%) had no chronic GVHD, 1 (14%) had limited GVHD and two (29%) had extensive GVHD.
Mortality
A total of 33 patients (57.8%) died between the start of treatment and the last follow-up. In total, 9 of the 15 patients undergoing allogeneic transplantation (60%) died, five (33%) from transplantrelated causes and four (27%) from tumor progression. Among the other 24 patients who did not undergo allogeneic transplantation, 16 patients died of tumor progression (including those patients Table 3 .
2. Chimerism. Data on chimerism were available for nine patients because of the loss of six patients due to early death. Complete donor chimerism was detected in 8/9 (89%) patients at day þ 28 and in all living patients (8/8) at day þ 100.
PFS and OS.
Median follow-up was 38 months (range:4.5-65.9 months). For the entire study population, median PFS was 7.1 months, with a plateau at 22%. Median OS was 21.4 months, with a plateau at 35% (Figure 1 ). For the 15 patients treated with allogeneic transplantation, both median PFS and OS were 32.6 months. There were six long-term survivors after allogeneic transplantation (40%), with follow-up times between 22 and 58 months (Figure 2 ).
Prognostic factors.
Several factors were analyzed for prognostic relevance, and IPI score was strongly associated with OS. Mortality was 92% for patients with 3-5 points, 53% for patients with 1-2 points and 17% for patients with 0 points (Po0.0001, log-rank test) (Figure 3) . Median survival was 6 months for patients with 3-5 points, 32.6 months for patients with 1-2 points and was not reached for patients with 0 points.
Regarding age, mortality was 45% for patients p50 years old and 65% for patients 450 years old (P ¼ 0.21, log-rank test). Median survival was 13.6 months in the older age group (450 years), but was not reached in the younger patients.
Patients with first relapse showed a trend toward more favorable OS compared with patients who had primary refractory disease (P ¼ 0.20, log-rank test). Between patients treated with early vs late first relapse, there was no difference for either PFS or OS.
DISCUSSION
In this study, patients with relapsed or refractory aggressive NHL were treated according to a risk-adapted strategy. All patients underwent high-dose chemotherapy with autologous hematopoietic SCT, and high-risk patients (defined by early relapse or primary refractoriness) also underwent allogeneic hematopoietic SCT.
A major obstacle to the application of the entire therapy protocol was disease progression before high-dose treatment in 32% of the patients. A similar 30% rate of induction failure during second-line treatment was seen in the CORAL trial. 15 In general, a high risk of early progression is now more common because patients receive rituximab during first-line treatment. 16, 17 Regarding toxicity and feasibility, high-dose TEC produced little non-hematological toxicity, other than reversible oral mucositis (grade 3, 50%; grade 4, 13%), possibly explained by the inclusion of etoposide in the high-dose protocol. Treosulfan as a single agent at high dose exerts little mucosal toxicity, 18 and we observed fewer cases of mucositis (43%, grades 3 and 4) in an earlier trial when treosulfan at the same dose was combined with either melphalan or thiotepa.
14 Patients who received prophylactic treatment with palifermin did not experience grade 4 mucositis, demonstrating the protective effect of this drug. 19 The treatment-related mortality after autologous transplantation (3%) within 30 days compares well with data reported in the literature of patients with lymphoma who have undergone a high- High-dose therapy for relapsed aggressive lymphoma M Koenigsmann et al dose therapy. 20, 21 Veno-occlusive disease, which is a risk factor after high-dose BU, 22 was not observed after high-dose TEC in our study.
Second high-dose therapy with auto-SCT, given to five patients, resulted in no grade 4 toxicity or mortality, which confirms our prior results showing the feasibility of double autologous transplantation in aggressive, relapsed lymphoma. 14 In patients receiving allogeneic transplantation after conditioning with treosulfan and fludarabine, grade I-III acute GVHD was seen in 54% of patients and extensive chronic GVHD in 29%, which compares well with published data regarding the same preparative regimen or carmustine, etoposide, cytarabine, and melphalan (BEAM)/fludarabine/TBI. 23, 24 Treatment-related mortality after allogeneic transplantation observed in 33% in our patients is similar to results of retrospective analyses and one prospective study of patients with aggressive lymphoma (25-43%). 7, 8, 24, 25 An even higher non-relapse mortality would be expected in our older study population (median age 53 years), as observed in patients older than 45 years. 25 A lower treatmentrelated mortality of 17% with the same preparative regimen of treosulfan and fludarabine was reported in patients with myelodysplastic syndromes, 23 likely resulting from the lower level of preceding intensive therapy. Our data show that allogeneic transplantation after autologous transplantation is feasible in patients with aggressive lymphomas.
Regarding efficacy, a high-dose therapy with TEC resulted in a response rate of 64% in our study. This rate is lower than that of the CORAL trial (86%), likely due to the higher proportion of patients with primary refractory disease in our study (37%) compared with that of the CORAL trial (11%). 15 While computed tomography was the only imaging modality used in this study, some of the responses classified as CR with residues might have been classified differently if positron emission tomography-computed tomography had been employed. A major advantage of using treosulfan in high-dose regimens is given by its lack of major hepatic toxicity, especially venoocclusive disease.
We report that 40% of the patients in our study were long-term survivors after allogeneic transplantation. A recent study of allogeneic transplantation in relapsed and refractory lymphoma patients reported 61% long-term survivors; however, this trial included patients with CLL. The small number of patients who underwent allogeneic transplantation in our trial does not allow statistical comparison. 24 An OS rate of 54% after 4 years was reported for patients with chemosensitive relapse after reducedintensity allogeneic transplantation for multiple relapsed aggressive NHL. 26 Whether reduced intensity or myeloablative conditioning should be used is still a matter of debate. 27 Our data show that allogeneic transplantation is also feasible in patients older than 50 years.
Interestingly, IPI was the strongest prognostic factor for patients who received second-line treatment, providing additional evidence for its validity as a predictor in the rituximab era 28 and outweighing the distinction between early and late relapse. The risk-adapted treatment of this study may have contributed to the equalization in OS of patients with early and late relapse, although the data and the skope of the study do not allow to prove this hypothesis. Our observation on the role of IPI requires testing in a prospective study.
Molecular differentiation of aggressive B-cell NHL had not been established when our trial began, however, it is now relevant, at least in clinical trials. 29 Thus, MYC rearrangements indicate poor response to salvage therapy with BEAM and autologous transplantation in the salvage therapy setting. 30, 31 Recently, a biologic prognostic model was established based on immunohistochemical staining in combination with IPI, providing a practical method for stratifying patients for riskadapted therapies. 32 Expanding on the data of our risk-adapted approach, we propose the following hypothetical treatment algorithm to be confirmed in prospective studies:
1. In the absence of additional risk factors, patients with low IPI should receive a high-dose therapy and auto-SCT. So far, for relapse after more than 5 years, a high-dose therapy is considered the treatment of first choice. 33 2. Patients with refractory disease and high IPI are candidates for allogeneic transplantation. If second-line cytoreductive treatment results in CR, patients should proceed directly to allogeneic transplantation to minimize additional toxicity. For patients with PR, further cytoreduction with a high-dose therapy and autologous transplantation is recommended before allogeneic transplantation. 3. Patients at high risk for induction failure during salvage therapy are candidates for new approaches before allogeneic transplantation. In this context, immunomodulatory drugs such as lenalidomide are being explored in combination with conventional chemotherapy. 34, 35 In conclusion, a risk-adapted, treosulfan-based high-dose therapy with auto-and allo-SCT is feasible for patients with relapsed or refractory aggressive NHL. Although a high-dose therapy followed by autologous transplantation is indicated in patients at relatively low risk, the role of allogeneic transplantation is relevant for high-risk patients, because long-term remissions can be achieved. Future trials should be based on IPI and include molecular characterization. In patients with induction failure, new compounds and approaches should be explored, such as maintenance therapy and combinations with radioimmunotherapy.
